Objective To study whether the HBC-A2/scFv fusion protein mediates killing of tumor cells by viral specific cytotoxic T cells. Methods The fusion protein was attached to the CD71-expressing, HLA class Ⅰ negative tumor cells. And then, cytolysis by viral peptide-specific CTLs which were generated by co-culture of peripheral blood lymphocytes from HLA-A2 positive donors with inactivated T2 cells pulsed with the viral peptide were tested by lactate dehydrogenase (LDH) releasing. Results The fusion protein can attach the active viral peptide/HLA-A2 complex to K562, HepG2 and U937 cells through binding of CD71 scFv to CD71 (37.30% ±8.25%, 27.20% ±3.88%, 21.80% ±6.49% ) and mediate cytotoxicity of viral peptide-specific CTLs against those cells in vitro ( K562: 42.08% ± 1.14% vs 8.07%± 1.39%; HepG2: 49.72% ± 1.59% vs 12.46% ± 1.26%; U937: 39.72% ± 3.26% vs 7.13% ±1.48% ). Conclusion This viral peptide/HLA-A2 complex targeted by CD71 scFv is able to redirect viral peptide-specific T-cell mediated immune responses against tumor cells.

Objective To evaluate immunofixation electrophoresis (IFE) and to compare it with conventional manual heat test method for detection of Bence Jones (BJ) protein in nonconcentrated urine. Methods We performed IFE and heat test for urinary protein analysis in 116 urine samples and evaluated a new immunofixation electrophoresis system by urinary protein analysis in 20 patients with multiple myeloma. Results 20 patients with multiple myeloma were detected to have BJ proteins (8 ? and 12?) in urine by IFE, whereas no urine BJ proteins by heat test. Conclusion The heat test for BJ proteins should be replaced by IFE because of its insensitivity and unspecificity. The IFE method is higherly sensitive and specific for screening and identification of BJ proteins in urine.